PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled " An Update on Hormonal Contraception and The Changing U.S. Population " will be presented by Co-Principal Investigator of the SECURE...
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at the interactive ePoster session during the 2017 Annual Clinical and Scientific Meeting of the American...
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla ® , an investigational low-dose combined...
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three and...
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women's healthcare company, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering....
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women's healthcare company, today announced the pricing of its underwritten public offering of 5,333,334 shares of its common stock at a public offering price of $3.75 per share....